Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4
Your skin just feels soft and smooth after
For clients who feel isolated in their weight loss efforts, the coaching and community structure can be the difference that keeps them going
The purity and precise amino-acid sequencing of a compound like our BPC 157 Peptide are non-negotiable for obtaining valid, repeatable data
No Phase 2 or Phase 3 clinical trial has been completed or published
From available case reports, compounding pharmacy data, and practitioner experience, the following have been observed: BPC-157 Reported Side Effects Nausea and gastrointestinal discomfort (especially with oral administration) Dizziness or light-headedness Flushing or warmth at injection sites Headache Fatigue or somnolence in some users TB-500 Reported Side Effects Injection site reactions (redness, mild pain, swelling) Transient fatigue or lethargy following administration Headache Possible flu-like symptoms in a minority of users Critical Risk Note: Because neither peptide has undergone full clinical trial evaluation in humans, the complete adverse event profile is unknown
